Clinical trials: Circulating Tumor Cell;
Recurrence, Metastasis
Clinical Relevance of NGS Analysis for High-purity CTC From Cancer Patients With Disruptive Gene Mutation(s)
Distant metastasis of cancer remains the major cause of cancer death. One of the evidence is that some rare cells shed from primary tumor exist in the circulation of cancer patients, which has been proven to be related to cancer…
- Conditions
- Recurrence, Metastasis, Death
- Trial name
- NCT03002350
- Where
- Taiwan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Cervical Cancer
Endothelial Progenitor Cells in Cervical Cancer Patients Receiving Chemoradiation
Invasive carcinoma of the uterine cervix remains the most common invasive cancer in women in many countries. Concurrent chemoradiotherapy (CCRT) is now recommended as a standard treatment for locally advanced and high-risk…
- Trial name
- EPC (NCT00753610)
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Mackay Memorial Hospital
Bladder Cancer, Circulating Tumor Cells
Detection and Clinical Significance of Circulating Cancer Cells in Patient Undergoing Radical Cystectomy
Very few factors may be identified as prognostic for patients with bladder cancer undergoing radical cystectomy. Recently, detection of circulating tumor cells has shown to be very promising in anticipating both the likelyhood of…
- Trial name
- CirCanCell (NCT02345473)
- Testing
- Detection of circulating tumor cells in blood samples
- Where
- Italy
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Diffuse Large B Cell Lymphoma
Kinetics of Circulating Tumor DNA in Lymphoma Treated by Immuno-chemotherapy
The purpose of this study is to determine the kinetics of circulating tumor DNA (ctDNA) in the hours following initial administration of immuno-chemotherapy to patients with diffuse large B cell lymphoma (DLBCL).
- Trial name
- LYMPHO-CLEAR (NCT06141772)
- Testing
- Measure of the circulating tumor DNA
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Centre Henri Becquerel
Carcinoma, Non-small Cell Lung Cancer
Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan
This is a single center, prospective and observational study conducted in three stages to predict the NSCLC lymph node metastasis based on ctDNA/specific methylation molecular features combined with PET-CT imaging features and…
- Trial name
- NCT06358222
- Testing
- Blood ctDNA + methylation + PET-CT and Postoperative pathology, MRD+ methylation (or combined with PET-CT) and Invasive mediastinoscopy /EBUS-TBNA, Intraoperative lymph node dissection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Chest Hospital
Breast Neoplasms, Neoplastic Cells, Circulating
Evaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer Patients
The phenotype of circulating tumor cells (CTCs) is supposed to be significant indicator that is correlated the prognosis of breast cancer patients who have completed neoadjuvant chemotherapy, primary tumor surgery with/without…
- Conditions
- Breast Neoplasms, Neoplastic Cells, Circulating, Chemotherapy Effect
- Trial name
- NCT05326295
- Testing
- CTC detection
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Hunan Cancer Hospital
Breast Cancer, Lung Cancer
Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)
This study will collect, annotate, and sequence biospecimens (blood, tissue, urine, saliva and surgery drainage) from patients across different cancer types to detect molecular residual disease (MRD).
- Conditions
- Breast Cancer, Lung Cancer, Melanoma, Gynecologic Cancer
- Trial name
- SHERLOCK (NCT07524114)
- Where
- Canada
- Volunteers
- 7,000 people
- Sponsor
- University Health Network, Toronto
Circulating Tumor Cells.Breast
The Detection of Circulating Tumor Cells (CTCs) in Breast Cancer With a Novel in Vivo Device
The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide which is CE approved. Application data of CellCollector in China is not available now.
- Trial name
- NCT03006055
- Testing
- Circulating tumor cells
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Beijing Viroad Biotechnology Co., Ltd.
Recurrence, Metastasis
The Clinical Relevance of Immune Cells and CTC in HNSCC Patients
Head and neck squamous cell carcinomas (HNSCCs) are mainly caused by tobacco, alcohol consumption and betel nut chewing and the sixth most common cancer in the world.
- Conditions
- Recurrence, Metastasis, Death
- Trial name
- NCT02420600
- Where
- Taiwan
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma
Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer
This study looks at the level of circulating tumor elements (cancer cells or DNA pieces floating in the blood) and how it may be related to how the tumor responds to standard treatment in patients with rectal cancer that has…
- Conditions
- Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Rectosigmoid Adenocarcinoma, Recurrent Rectal Adenocarcinoma
- Trial name
- NCT02874885
- Testing
- Biospecimen Collection
- Where
- United States
- Volunteers
- 341 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Objective Responsive Rate (ORR)
Dynamic Changes in Circulating Tumour Cells Protein Expression
This multicenter study, randomized, controlled of blood-based biomarker-driven targhet therapy. Patients were selectedm( at Hospital San Giovanni and Celio in Rome) according to CTCs results ( CTCs-guided managment performed at…
- Trial name
- Liquid-DRER2 (NCT06314997)
- Testing
- panitumumab (EGFR inhibitors)
- Where
- Italy
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Matteo's Friends
Neuroblastoma
Serial ctDNA and Molecular Residual Disease Monitoring in Neuroblastoma
This prospective observational study evaluates serial circulating tumor DNA (ctDNA) and molecular residual disease (MRD) monitoring in patients with neuroblastoma.
- Trial name
- NCT07516678
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Head and Neck Neoplasm, Carcinoma, Squamous Cell
Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma
Circulating tumor DNA (ctDNA) is a blood-based test that measures dying or dead cancer cells that are already circulating in the blood.
- Trial name
- NCT04099290
- Testing
- Blood and tumor samples
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Gastric Cancer
HER2 Circulating Tumor Cells in Gastric Cancer
The investigators propose to survey the frequency of HER2 (+) CTC in order to lay groundwork for future clinical trials incorporating Her-2 targeted agents in gastric cancer.
- Trial name
- NCT01299688
- Where
- South Korea
- Volunteers
- 135 people
- Sponsor
- Samsung Medical Center
Cervical Dysplasia, Uterine, Vaginal Dysplasia
Clinical, Translational and Biomarker-Based Female Genital HPV Induced Dysplasia and Cancer Screening Study Using Cf-HPV-DNA Blood Tests
Uterine cervical dysplasia and other female genital dysplasia continue to be significant health problems despite Cervical Screening Programs and HPV vaccinations being available.
- Conditions
- Cervical Dysplasia, Uterine, Vaginal Dysplasia, Vulvar Dysplasia
- Trial name
- TTMV HPV DNA (NCT05536843)
- Volunteers
- 500 people
- Sponsor
- University of Mississippi Medical Center
Triple Negative Breast Cancer, Natural Killer Cells
A Pilot Surveillance Study to Monitor Natural Killer Cells and Circulating Tumor Cells in Women With Previously Treated Non-metastatic Triple Negative Breast Cancer and Women With Previously Treated Non-metastatic Breast Cancer With a Confirmed BRCA Mutation.
The purpose of this research study is: To test blood for the presence of tumor derived circulating tumor cells (CTCs) or circulating tumor DNA (ctDNA) using an investigational medical device called the LiquidBiopsy®.
- Conditions
- Triple Negative Breast Cancer, Natural Killer Cells, BRCA Mutation
- Trial name
- NCT02639832
- Testing
- LiquidBiopsy®, NK VueTM
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- Cynvenio Biosystems
Squamous Cell Carcinoma
Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC
A single-arm, phase II study for patients with detectable HPV CtDNA at 12 weeks or longer after completion of definitive therapy for non-metastatic, HPV+ squamous cell carcinoma.
- Trial name
- NCT06762808
- Testing
- Atezolizumab, Talazoparib
- Sponsor
- M.D. Anderson Cancer Center
Lung Neoplasms
Circulating Tumor Cells (CTC) in Lung Cancer
The primary objective of this study is to establish circulating tumor cell (CTC) derived xenografts and assess the activity of novel DNA repair inhibitors as a function of DNA repair mutations detected in CTC samples (personalize…
- Trial name
- NCT02630615
- Testing
- Blood draw
- Where
- 2 sites in United States
- Volunteers
- 71 people
- Sponsor
- Shadia Jalal
Cancer, Metastasis Lung
Relationship Between Circulating Tumor Cell Cultures' Treatment Response and Clinical Outcomes
The purpose of this prospective, non-randomized, single-center pilot exploratory study is to investigate whether established circulating tumor cell (CTC) cultures have a similar response to targeted therapy treatment as the in…
- Conditions
- Cancer, Metastasis Lung, Metastasis to Liver, Circulating Tumor Cell
- Trial name
- NCT04280640
- Testing
- Blood Draw
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Lung Cancer Recurrent
Recurrent Predictive Power of Circulating Tumor Cells for Non Small Cell Lung Cancer Patients
From literature review, circulating tumor cell was demonstrated its possible role in disease relapse. It was rare nit could be identified in all lung cancer patients.
- Trial name
- NCT03721133
- Where
- Taiwan
- Volunteers
- 150 people
- Sponsor
- Chang Gung Memorial Hospital